GID BIO Blog

While minimally invasive treatments transformed cardiology decades ago, advancements in orthopedic medicine are introducing potential alternatives to traditional surgery by

AMA grants two Category III CPT® codes, paving the way for reimbursement strategies   GID BIO’s unique autologous cellular implant

GID BIO completed a pivotal Phase IIb clinical trial with an FDA-compliant study design using autologous stromal cells in the

Interventional Orthopedics and cell-based therapy Companies and clinics tout the promise of cellular therapy (usually as a “stem cell therapy”)